Sign in

CIK 0001841387 · <br>Emerging growth company

Candel Therapeutics, Inc.

Sign in to watch
Ticker
CADL
Exchange
Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
FY end
Dec 31
Incorporated
DE
Entity type
operating
EIN
522214851
Phone
617-916-5445
Business address
117 KENDRICK STREET, SUITE 450, NEEDHAM, MA, 02494
  1. 4 Planned sale Chief Technology Officer sold 31,278 shares at $8.82 ($275,947)
  2. 4 Planned sale See Remarks sold 5,000 shares at $8.83 ($44,169)
  3. 4 Returned to the company 10% owner returned 21,165 shares (to the company)
  4. 4 Derivatives Options or other derivatives
  5. 4 Derivatives Options or other derivatives
  6. 4 Derivatives Options or other derivatives
  7. 4 Derivatives Options or other derivatives
  8. 4 Derivatives Options or other derivatives
  9. 4 Returned to the company 10% owner returned 31,335 shares (to the company)
  10. 4 Open-market sale Chief Scientific Officer sold 13,534 shares at $7.23 ($97,783)
  11. 4 Open-market sale Chief Technology Officer sold 14,322 shares at $7.23 ($103,476)
  12. 4 Open-market sale See Remarks sold 9,511 shares at $7.23 ($68,717)
  13. 4 Open-market sale Chief Executive Officer sold 21,704 shares at $7.23 ($156,811)
  14. 4 Open-market sale Chief Medical Officer sold 10,428 shares at $7.23 ($75,342)
  15. 4 Open-market sale Chief Scientific Officer sold 13,673 shares at $8.22 ($112,367)
  16. 4 Open-market sale See Remarks sold 9,971 shares at $8.22 ($81,944)
  17. 4 Open-market sale Chief Executive Officer sold 21,172 shares at $8.22 ($173,996)
  18. 4 Open-market sale Chief Technology Officer sold 14,545 shares at $8.22 ($119,534)
  19. 4 Open-market sale Chief Medical Officer sold 10,799 shares at $8.22 ($88,749)
  20. 4 Returned to the company 10% owner returned 200,000 shares (to the company)

Page 4 of 11 · 202 filings